ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2017 American Transplant Congress

    Antibody Mapping by Protein Microarray Revealed a Unique Repertoire in Lung Transplant Recipients That Developed Chronic Lung Allograft Dysfunction.

    D. Nayak,1 K. Garcia,2 P. Pirrotte,2 R. Hachem,3 R. Bremner,1 M. Smith,1 T. Mohanakumar.1

    1Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ; 2Translational Genomics Research Institute, Phoenix, AZ; 3Washington University, St. Louis, MO

    Background: Development of chronic lung allograft dysfunction (CLAD) limits long-term success from lung transplantation (LTx). Elicitation of de novo antibody (Ab) to mismatched donor HLA…
  • 2017 American Transplant Congress

    Multiple Dosing of Anti-C1s Antibody TNT009 – Effect on HLA Antibody-Triggered Complement Activation in Healthy Volunteers and Kidney Transplant Recipients with Antibody-Mediated Rejection.

    J. Muhlbacher,1 B. Jilma,2 M. Wahrmann,3 F. Eskandary,3 J. Gilbert,4 S. Panicker,4 G. Böhmig.3

    1Department of Surgery, Medical University Vienna, Vienna, Austria; 2Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria; 3Department of Medicine III, Medical University Vienna, Vienna, Austria; 4True North Therapeutics, Inc., San Francisco, CA

    Study purpose. Complement inhibition may be an attractive strategy to prevent antibody-mediated allograft injury. One promising therapeutic target may be the enzymatic activity of key…
  • 2017 American Transplant Congress

    2B4-Mediated Inhibition of Proliferation and Glycolytic Function Attenuates T Cell Alloreactivity.

    S. Laurie, D. Liu, M. Cortes, M. Wagener, M. Ford.

    Emory Transplant Center, Atlanta, GA

    Current thinking holds that costimulation-blockade resistant graft rejection may be mediated by CD28null T cells. To further investigate this possibility, we performed a retrospective immunophenotypic…
  • 2017 American Transplant Congress

    Applicability and Safety of a Regulatory T Cell Therapy in Adult Liver Transplantation: The “ThRIL” Phase I First-in-Human Trial.

    G. Whitehouse, N. Safinia, S. Thirkell, L. Fry, N. Grageda, M. Martinez-Llordella, R. Lechler, N. Heaton, G. Lombardi, A. Sanchez-Fueyo.

    MRC Centre for Transplantation, King's College London, London, United Kingdom

    Aim“ThRIL” is a multiple site, open-label, uncontrolled, phase I clinical trial assessing the safety and applicability of a CD4+CD25+FOXP3+ regulatory T cell (Treg) immunotherapy in…
  • 2017 American Transplant Congress

    Kidney Injury Molecule-1 Mitigates Tissue Damage from Transplant Renal Ischemia Reperfusion Injury.

    J. Lee,1,2 X. Zhang,2 A. Haig,3 D. Lian,2 P. Anderson,2 R. Navaratnam,2 L. Gunaratnam.1,2

    1Department of Microbiology and Immunology, Western University, London, ON, Canada; 2Matthew Mailing Centre for Translational Transplant Studies, London Health Sciences Centre, London, ON, Canada; 3Department of Pathology, Western University, London, ON, Canada

    Ischemia reperfusion injury (IRI) at the time of organ harvesting is unavoidable, may cause delayed renal graft function, and is associated with premature graft loss.…
  • 2017 American Transplant Congress

    Chagas Disease and Outcome in Kidney Transplant.

    M. Taylor, A. Martinoia, S. Di PIetrantonio, M. Torres, H. Petrone.

    Renal Transplant Unit, CRAI Sur - CUCAIBA, La Plata, Buenos Aires, Argentina

    Introduction: Chagas disease is one of the most expanded endemic in Latin America with 8 people from every 10.000.000 being infected. In Argentina its estimated…
  • 2017 American Transplant Congress

    Contemporary Outcomes and Risk Factors of Acute Graft-versus-Host Disease After Liver Transplant.

    J. Markus, A. Bukannan, B. Kashat, R. Salgia.

    Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI

    Introduction:Acute graft-versus-host-disease (GVHD) is a rare complication of orthotopic liver transplant (LT) that has an estimated incidence of 0.1%-2% per year. This complication of OLT…
  • 2017 American Transplant Congress

    Epigenetic Modifications in the Progression to Chronic Renal Allograft Injury.

    V. Bontha,1 D. Maluf,1 M. Dozmorov,2 K. Archer,3 L. Gallon,4 V. Mas.1

    1UVA, Charlottesville; 2VCU, Richmond; 3OSU, Columbus; 4NWU, Chicago

    Background: The renal allograft is exposed to a milieu of environmental/metabolic stimuli that trigger epigenetic modifications and thereby gene expression patterns which influence function and…
  • 2017 American Transplant Congress

    Early Results of the UK REVIVE Trial for Ex-Vivo Liver Warm Blood Perfusion of DCD and DBD Livers Using the Portable Organ Care System (OCS™) Liver Technology.

    D. Vijayanand, F. Zahreldeen, J. Kingston, S. Farid, T. Mdlongwa, A. Ramsden, S. Willis, C. Moriarty, M. Attia.

    Hepatobiliary and Transplant Surgery, The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

    Purpose:TheOCS Liver REVIVE Trial is a single-arm prospective trial to evaluate the safety and performance of OCS™ Liver system to preserve and assess DCD and…
  • 2017 American Transplant Congress

    Lower Incidence of DSA-Induced Chronic Antibody-Mediated Rejection in Abo-Incompatible Renal Transplantation.

    M. Okada,1 Y. Watarai,1 K. Iwasaki,2 K. Futamura,1 T. Hiramitsu,1 M. Tsujita,1 N. Goto,1 S. Narumi,1 T. Kobayashi.2

    1Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; 2Transplant Surgery, Aichi Medical University, Nagakute, Japan

    <INTRODUCTION>Current progress in immunosuppressive therapy has successfully controlled ABO-incompatibility in renal transplantation, although donor specific HLA antibody (DSA) is still insurmountable. Our in vitro experiments…
  • « Previous Page
  • 1
  • …
  • 124
  • 125
  • 126
  • 127
  • 128
  • …
  • 181
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences